The CEO of Awridian Ltd was at this RSC meeting on 7th March.
A synopsis From the RSC website:
Conformational Design has played a key role in the medicinal chemistry of small molecule clinical candidates over the last 20 years. A key learning from multiple projects supported by experimental free ligand NMR solution conformations and protein-ligand X-ray structures is that the bioactive conformation of potent ligands is highly populated in solution. Ligand rigidification has been particularly successful in the design of selective and potent protein-protein interaction inhibitors and is becoming an increasingly important approach for PROTACs, molecular glues and other new modalities. This new RSC-BMCS event aims at building a community that shares conformational design strategies, technologies, and successful case studies. It will complement other rational drug design events and promote more successful research into future medicines.